Androgenetic Alopecia
Conditions
Interventions
Experiment Group:One hundred units of botulinum toxin type A are reconstituted in autologous platelet-rich plasma and administered via intradermal injection in the alopecic area, at a dose of 0.1 mL p
Control Group:Autologous platelet-rich plasma is injected intradermally in the alopecic area, at a dose of 0.1 mL per point, for a total of 30 points, with an interval of 1 cm between injection points
Sponsors
Nanfang Hospital, Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Patients who meet the diagnostic criteria for AGA, confirmed by medical history, clinical presentation, and trichoscopy, with a stage of Norwood-Hamilton III to V or Ludwig I to III. 2.Patients provide informed consent and voluntarily participate in the study. 3.A signed informed consent form is obtained. 4.Age between 18 and 60 years, in good general health. 5.No use of any medications for AGA treatment within the past 6 months. 6.Absence of alopecia areata, local infection, or neuromuscular diseases.
Exclusion criteria
Exclusion criteria: 1.Disease duration exceeding 5 years. 2.Patients who do not meet the diagnostic criteria for AGA. 3.Individuals with coagulation disorders. 4.Patients with active skin diseases or other severe systemic illnesses. 5.Patients with blood-borne infectious diseases such as Hepatitis A, Hepatitis B, HIV/AIDS, or Syphilis. 6.Use of any medications for hair loss treatment within the past 6 months. 7.Other conditions deemed by the investigator as unsuitable for participation, including but not limited to unreliable patients, or those unable to undergo or comprehend the study assessments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair Density; | — |
Countries
China
Contacts
Public ContactMiao Yong
Nanfang Hospital, Nanfang Medical University
Outcome results
None listed